Anti-hIL-4R-hIgG4 (S228P)
-
Cat.code:
hil4r-mab14
- Documents
ABOUT
Anti-human IL-4R alpha - Dupilumab biosimilar - CAS #1190264-60-8
Anti-hIL-4R-hIgG4 (S228P) is a biosimilar antibody of Dupilumab, a human interleukin 4 receptor alpha (IL-4Rα) antibody that blocks both IL-4 and IL-13 signaling. This monoclonal antibody (mAb) is FDA-approved for the treatment of asthma, atopic dermatitis, and chronic sinusitis.
Anti-hIL-4R-hIgG4 (S228P) comprises the variable region of Dupilumab and the IgG4 (S228P) constant region of Dupilumab for low/no effector functions.
This antibody can be used together with HEK-Blue™ IL-4/IL-13 cells for screening and neutralization assays to block IL-4R signaling induced by recombinant human IL-4 or IL-13 (see figure).
Key features
- Each lot is functionally tested and validated
- The complete sequence of the antibody construct has been verified
- Absence of endotoxins determined by the EndotoxDetect assay
All products are for research use only, and not for human or veterinary use.
InvivoGen also offers:
SPECIFICATIONS
Specifications
IL-4Rα (CD124)
Human
Neutralization assay, ELISA, Fc interaction studies
Sodium phosphate buffer with glycine, saccharose, and stabilizing agents
Neutralization assay
Each lot is functionally tested and validated.
CONTENTS
Contents
-
Product:Anti-hIL-4R-hIgG4 (S228P)
-
Cat code:hil4r-mab14
-
Quantity:100 µg
Shipping & Storage
- Shipping method: Room temperature
- -20°C
- Avoid repeated freeze-thaw cycles
Storage:
Caution:
Details
Dupilumab background
Dupilumab is a fully human monoclonal antibody (mAb) that targets the human IL-4 receptor alpha subunit (CD124) of the type I and type II IL-4 receptors [1]. It acts like a receptor antagonist and inhibits signaling of both IL-4 and IL-13 [1]. This antibody contains an engineered hinge region mutation (S228P) designed to prevent the exchange of IgG4 molecules [1]. Dupilimab has shown efficacy across multiple Th2 cellular inflammatory disorders and is approved for treating asthma, atopic dermatitis, and chronic sinusitis [1-2]. Due to its favorable safety profile and established clinical use, Dupilumab holds significant promise for amending treatment options for a plethora of dermatologic conditions [3].
References:
1. Harb H, Chatila TA, 2020. Mechanisms of Dupilumab. Clin Exp Allergy. 50(1):5-14.
2. U.S. Food and Drug Administration (FDA) (Report). 2018. New Drug Therapy Approvals 2018.
3. Olbrich H, et al., 2023. Dupilumab in Inflammatory Skin Diseases: A Systematic Review. Biomolecules.13(4):634.
DOCUMENTS
Documents
Technical Data Sheet
Validation Data Sheet
Safety Data Sheet
Certificate of analysis
Need a CoA ?
